Emerging drugs for schizophrenia
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND/OBJECTIVE: Schizophrenia is a chronic and disabling psychiatric disorder that requires lifelong medication. The past 15 years led to the introduction of a number of new drugs ('atypical') that have dramatically displaced the older drugs ('typical'), at least in Western markets. As the dust settles on this period and substantial data, as well as practical prescribing experience, are available, we examine what has been gained and what can be learned. METHODS: Information available from various medical database resources: MEDLINE, EMBASE, Cochrane Database, ClinicalTrials.gov (a registry of federally and privately supported clinical trials) and schizophreniaforum.org--Drugs in Clinical Trials for Schizophrenia. RESULTS/CONCLUSION: It seems that the clinical benefits of the newer second-generation antipsychotics are modest, the greatest advantage being a reduction in motor side effects. The earlier hope that these agents have a primary effect on negative and cognitive symptoms is harder to sustain. Clozapine remains superior, even to other atypical antipsychotics, in treating refractory schizophrenia. On a mechanistic level, it seems that dopamine D(2) blockade is necessary and even sufficient for antipsychotic response (at least in some), though other receptors may contribute in ways that are not yet well understood.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140 · cited 2×
“In support of this position, it was argued that lower affinity at the D 2 receptors is a better predictor of atypicality than the 5-HT 2 affinity of an atypical antipsychotic [26,27] .”
BackgroundSelf-citationPatil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040 · cited 3×
“A recent double-blind study investigating LY2140023 versus placebo and olanzapine in patients with schizophrenia showed statistically significant improvements in both positive and negative symptoms for LY2140023 compared to placebo after 4 weeks of treatment [93] .”
BackgroundNMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020 · cited 1×
“The hypothesis was further supported by magnetic resonance spectroscopy, post-mortem studies and gene association data suggesting alterations in glutamate metabolites and in the glutamate receptors in patients with schizophrenia [88-90] .”
ResultMiyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · cited 1×
“Finally, there is considerable excitement that the identification of genetic mechanisms underlying illnesses such as schizophrenia will reveal new targets for drug development [185] .”
BackgroundGlutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917 · cited 1×
“These same drugs have been shown to induce relapse of psychotic symptoms in previously stabilized patients with schizophrenia [86] , and unmedicated patients with schizophrenia were found to be more sensitive than normal volunteers to the effects of NMDA antagonists [87] .”
BackgroundAtypical antipsychotics: Mechanism of action
Seeman, P. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700106 · Cited by 899
Seeman, P., & Lee, T. (1975) · Science · doi:10.1126/science.1145194 · Cited by 869 · cited 1×
“The finding of CPZ’s antipsychotic activity was serendipitous, and over the next decade it was established that it was very likely the blockade of dopamine (DA), in particular the D 2 receptors, that accounted for this effect [5,6] .”
BackgroundPrefrontal Dopamine D1Receptors and Working Memory in Schizophrenia
Abi-Dargham, A., Mawlawi, O., Lombardo, I., Gil, R., Martinez, D., Huang, Y., Hwang, D.-R., Keilp, J., Kochan, L., Van Heertum, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03708.2002 · Cited by 724 · cited 2×
“Within this framework, neurocognitive and negative symptoms, for example, are better understood as reflecting hypo- rather than hyperdopaminergic states [37,38] .”
BackgroundSchizophrenia, sensory gating, and nicotinic receptors
Adler, L. E., Olincy, A., Waldo, M., Harris, J. G., Griffith, J., Stevens, K., Flach, K., Nagamoto, H., Bickford, P., Leonard, S., et al. (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033320 · Cited by 690
Half a century of antipsychotics and still a central role for dopamine D2 receptors
Kapur, S., & Mamo, D. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.004 · Cited by 638 · cited 1×
“Alternatively, and in line with the aforementioned shift in drug development, schizophrenia may well represent a collection of different pathophysiological mechanisms, and optimal treatment in the future will probably include different agents, each uniquely targeting a specific dimension of schizophrenia and treatment…”
BackgroundSelf-citationArnsten, A. F. T., & Goldman-Rakic, P. S. (1985) · Science · doi:10.1126/science.2999977 · Cited by 549
Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419
Arnsten, A., Cai, J., & Goldman-Rakic, P. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-11-04287.1988 · Cited by 391 · cited 1×
“Guanfacine is a recently developed selective alpha 2 agonist that has demonstrated preclinical efficacy in reversing working memory deficits [133] .”
BackgroundSchizophrenia and the α7 Nicotinic Acetylcholine Receptor
Martin, L. F., & Freedman, R. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78008-4 · Cited by 213
Galantamine for the treatment of cognitive impairments in people with schizophrenia
Buchanan, R. W., Conley, R. R., Dickinson, D., Ball, M. P., Feldman, S., Gold, J. M., & McMahon, R. P. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07050724 · Cited by 170
Tauscher, J., Hussain, T., Agid, O., Verhoeff, N. P. L. G., Wilson, A. A., Houle, S., Remington, G., Zipursky, R. B., & Kapur, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1620 · Cited by 159 · cited 1×
“Two commonly used FGAs (flupentixol and zuclopenthixol) have a near-equivalent balance of D 1 and D 2 receptor activity [62] , and clozapine’s pharmacological profile represents low affinity for the D 2 receptor in the face of considerable affinity for D 1 receptors [63,64] .”
Self-citationMaes, M. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00062-0 · Cited by 156 · cited 1×
“, an overactivation of type 2 immune response together with suppression of type 1 response) [175] .”
BackgroundGuanfacine treatment of cognitive impairment in schizophrenia
Friedman, J. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00249-4 · Cited by 113 · cited 1×
“A recent 4-week, doubleblind study evaluating guanfacine versus placebo as an add-on treatment to ongoing SGA treatment failed to substantiate this claim, although trends were reported for spatial working memory and continuous performance task (CPT) reaction time [134,135] .”
BackgroundSPORN, A. L., VERMANI, A., GREENSTEIN, D. K., BOBB, A. J., SPENCER, E. P., CLASEN, L. S., TOSSELL, J. W., STAYER, C. C., GOCHMAN, P. A., LENANE, M. C., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31812eed10 · Cited by 107 · cited 1×
“Superior clinical outcome was found in subjects with greater NDMC to clozapine plasma concentration ratios [157,158] .”
Background
Cited by
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
van Os, J., & Kapur, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60995-8 · Cited by 1,971
Self-citationMiyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
The role of kinetic context in apparent biased agonism at GPCRs
Klein Herenbrink, C., Sykes, D. A., Donthamsetti, P., Canals, M., Coudrat, T., Shonberg, J., Scammells, P. J., Capuano, B., Sexton, P. M., Charlton, S. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10842 · Cited by 328
Metadata
- Authors
- Agid, O., Kapur, S., & Remington, G.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa UK Limited
- Published
- 2008-09
- Volume
- 13
- Issue
- 3
- Pages
- 479-495
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2096633081
- Cited by
- 65
- References
- 24
- FWCI
- 7.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.